Clinical Trials Logo

Post-stroke Depression clinical trials

View clinical trials related to Post-stroke Depression.

Filter by:

NCT ID: NCT05187975 Not yet recruiting - Clinical trials for Post-stroke Depression

Integrated Rehabilitation in Treating Post-stroke Depression

IRTPD
Start date: January 30, 2022
Phase: N/A
Study type: Interventional

Post-stroke depression (PSD) is a common complication of stroke that leads to dysfunction and reduces the quality of life. PSD exacerbates cognitive dysfunction, delays the recovery process, and increases the disability, mortality and recurrence rates of stroke. Therefore, early clinical treatments for PSD are important to improve the prognosis and restore the social functions of stroke patients. Integrated rehabilitation has significant advantages in the treatment of PSD. First of all, there is a wide range of rehabilitation methods, such as acupuncture, traditional Chinese medicine, and repetitive transcranial magnetic stimulation, which have been proved to be effective for PSD. However, as the application of integrated rehabilitation becomes more and more widespread, its shortcomings are gradually emerging. For example, most of the treatment protocols used in clinical studies are based on personal experience of the investigators, a unified protocol has not yet been formed; treatment methods are still insufficient in standardization and reproducibility. More studies focus solely on the improvement of a certain symptom by a certain rehabilitation therapy, but ignore the important theoretical basis of the "holistic concept", thus showing the uneven clinical efficacy. For the above existing problems, it is necessary to conduct original and innovative research.

NCT ID: NCT04876066 Recruiting - Clinical trials for Post-stroke Depression

Use of Transmucosal Ketamine in Post Stroke Depression

Start date: November 30, 2020
Phase: Phase 1
Study type: Interventional

Studies have shown that ketamine is very effective and has a quick onset in treatment of depression. Most of these studies used intravenous ketamine in an inpatient setting and there are no large trials examining its use in Post Stroke Depression (PSD). There have been only few studies that have used other routes of administration (i.e., oral, transmucosal, intranasal, intramuscular) of ketamine which provided symptom relief for depression. The purpose of this study is to assess the effectiveness and safety of use of transmucosal ketamine in treatment of PSD. We hypothesize that fast acting antidepressant effects can be achieved with tolerable side effects for translation into the general post-stroke population. To test our hypothesis, the specific aim is to: (1) demonstrate that transmucosal administration of ketamine is feasible within the post-stroke depression population and has tolerable side effects. Exploratory aims will include assessment if ketamine also produces fast acting antidepressant effects.

NCT ID: NCT04560413 Completed - SARS-CoV-2 Clinical Trials

Depression, Anxiety and SARS-CoV-2 (Covid-19) Phobia in Post-stroke Patients

Start date: June 1, 2020
Phase:
Study type: Observational

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has begun, first in Wuhan, China, and then became a pandemic. The first SARS-CoV-2 case in Turkey was reported on March 11, 2020. People older than 65 years old became subject to lock down measures beginning on March 21, while people younger than 20 years old became subject to lock down measures beginning on April 03. A total lock down has been implemented a few times lasting between 3 to 4 days, especially at weekends. Several studies show that mental health problems could occur in public during the SARS-CoV-2 pandemic. Depression and anxiety are a commonly known mental health issue in post-stroke patients. This patient population, who usually have to spend most of their time at home, remained completely at home and socially isolated due to the precautions required by the pandemic. Based on the above research evidence; depression, anxiety and phobia of SARS-CoV-2 may increase in the post stroke patients due to being in risk group and effects of measures taken against SARS-CoV-2 pandemic. Therefore, we aimed to assess the depression, anxiety and SARS-CoV-2 phobia in post stroke patients during SARS-CoV-2 outbreak, and to explore the potential influence factors.

NCT ID: NCT04318951 Recruiting - Clinical trials for Post-stroke Depression

Impact of Intensive Social Interaction on Post-Stroke Depression in Individuals With Aphasia: A Proof-of-Concept Trial

Start date: March 1, 2020
Phase: N/A
Study type: Interventional

The present controlled, parallel-group, single-center, blinded-assessment, phase-IIA trial seeks to explore the feasibility of a study protocol on intensive communicative-pragmatic social interaction as a means to promote recovery from post stroke depression in the late subacute or consolidation phase of aphasia. The primary hypothesis predicts significantly greater progress on self-report and clinician-rated measures of depression severity after (i) intensive communicative-pragmatic social interaction combined with standard care, compared to (ii) standard care alone. Likewise, secondary hypotheses predict that intensive communicative-pragmatic social interaction leads to significantly improved performance on measures evaluating self-efficacy and quality of life.

NCT ID: NCT04283591 Completed - Anxiety Disorders Clinical Trials

The Effectiveness of Acupuncture Treatment for Post-Stroke Depression and Anxiety Disorder.

Start date: August 1, 2019
Phase: N/A
Study type: Interventional

Poststroke depression is seen with a frequency of up to 30%. Drug options for depression and accompanying sleep problems are limited; In addition, effective doses cannot be increased depending on the comorbidities of the patients and the side effect profiles and drug interactions of the drugs used. Acupuncture has been used in Chinese traditional medicine for more than 2000 years and there are findings that it has positive effects in post-stroke depression and anxiety disorders. The aim of this study is to examine the effectiveness and reliability of acupuncture treatment in depression and anxiety disorders developing after stroke and to reduce the need for multiple drugs and / or high-dose medication in the treatment of these complications. The hypothesis of the study: Acupuncture is an effective and reliable treatment method for depression and anxiety disorders in stroke patients.

NCT ID: NCT04093843 Recruiting - Clinical trials for Post-stroke Depression

TMS for Post Stroke Depression

Start date: October 24, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to find alternative treatments for patient's suffering from depression after having a stroke.This study aims to show that accelerated rTMS is a safe, effective,and convenient treatment for patient's suffering from post-stroke depression in the acute to subacute phase. This will be an open label trial and thus all participants will receive the active rTMS intervention.

NCT ID: NCT04008719 Completed - Clinical trials for Post-stroke Depression

ATtention Test and Executive Functions After STroke to Predict Depression.

ATTEST-Depress
Start date: May 16, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether cognitive function evaluation (sustained attention, executive functions, working memory) during acute post-stroke is predictive of a 3 months post-stroke depression.

NCT ID: NCT03903068 Recruiting - Clinical trials for Post-stroke Depression

Transcranial Alternating Current Stimulation Treating Post-stroke Depression

Start date: August 15, 2019
Phase: N/A
Study type: Interventional

Post-stroke depression (PSD) is one of the most common complications after stroke, with a high prevalence. PSD can affect prognosis and rehabilitation of stroke, increase risks of mortality and suicide, and escalate the economic burden on individuals and society. Studies have shown that transcranial alternating current stimulation (tACS) can also be used to treat depression, insomnia and anxiety. So far, this stimulator has been approved by FDA. However, there have not been any reports on the use of tACS in the treatment of depression and PSD in China. In this trial, the efficacy and safety of the tACS will be assessed with the rigor methodology manner.

NCT ID: NCT03864484 Recruiting - Clinical trials for Post-stroke Depression

iPad Application-based Intervention for Post-stroke Depression

Start date: May 7, 2019
Phase: N/A
Study type: Interventional

We plan to conduct a randomized controlled trial to examine whether usual rehabilitation plus an iPad application-based intervention improves post-stroke depression symptoms compared to usual rehabilitation alone. The purpose of this pilot randomized controlled trial is to investigate the feasibility of the final randomized controlled trial.

NCT ID: NCT03829397 Completed - Clinical trials for Post-stroke Depression

To Investigate the Correlation of Stroke Patients and Demoralized

Start date: February 18, 2019
Phase:
Study type: Observational

This study aim to clarify the participants's mental state with Demoralization Scale- Mandarin Version(DS-MV). Based on clinical observations and literature review, investigators assume participants's DS-MV score high correlation with PHQ-9 score.